Effective lethal mutagenesis of influenza virus by three nucleoside analogs

Journal of Virology

Volumn 89, Issue 7, 2015, Pages 3584-3597

  Pauly, Matthew D ^a   Lauring, Adam S ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZACITIDINE; FLUOROURACIL; MYCOPHENOLIC ACID; RIBAVIRIN; NUCLEOSIDE;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIVIRAL ACTIVITY; ARTICLE; CELL DEATH; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG POTENCY; INFLUENZA; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; MDCK CELL LINE; MUTAGENIC ACTIVITY; NONHUMAN; PRIORITY JOURNAL; VIRUS INFECTIVITY; VIRUS MUTATION; VIRUS REPLICATION; VIRUS TITRATION; ANIMAL; ANTIVIRAL RESISTANCE; CELL LINE; DOG; GENETICS; INFLUENZA A VIRUS (H1N1); INFLUENZA A VIRUS (H3N2); METABOLISM; MICROBIAL VIABILITY; MUTAGENESIS; PHYSIOLOGY; VIRUS CULTURE;

ORTHOMYXOVIRIDAE; RNA VIRUSES;

ANIMALS; AZACITIDINE; CELL LINE; DOGS; DRUG RESISTANCE, VIRAL; FLUOROURACIL; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; MICROBIAL VIABILITY; MUTAGENESIS; NUCLEOSIDES; RIBAVIRIN; SERIAL PASSAGE; VIRUS CULTIVATION; VIRUS REPLICATION;

EID: 84924767317     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.03483-14     Document Type: Article

References (67)

1. Steinhauer DA, Skehel JJ. 2002. Genetics of influenza virus. Annu Rev Genet 36:305-332. http://dx.doi.org/10.1146/annurev.genet.36.052402.152757.
2. Aggarwal S, Bradel-Tretheway B, Takimoto T, Dewhurst S, Kim B. 2010. Biochemical characterization of enzyme fidelity of influenza A virus RNA polymerase complex. PLoS One 5:e10372. http://dx.doi.org/10.1371/journal.pone.0010372.
3. Ruigrok RW, Crépin T, Hart DJ, Cusack S. 2010. Towards an atomic resolution understanding of the influenza virus replication machinery. Curr Opin Struct Biol 20:104-113. http://dx.doi.org/10.1016/j.sbi.2009.12.007.
4. Sanjuan R, Nebot MR, Chirico N, Mansky LM, Belshaw R. 2010. Viral mutation rates. J Virol 84:9733-9748. http://dx.doi.org/10.1128/JVI.00694-10.
5. Shiraishi K, Mitamura K, Sakai-Tagawa Y, Goto H, Sugaya N, Kawaoka Y. 2003. High frequency of resistant viruses harboring different mutations in amantadine-treated children with influenza. J Infect Dis 188:57-61. http://dx.doi.org/10.1086/375799.
6. Ghedin E, Holmes EC, DePasse JV, Pinilla LT, Fitch A, Hamelin M-E, Papenburg J, Boivin G. 2012. Presence of oseltamivir-resistant pandemic A/H1N1 minor variants before drug therapy with subsequent selection and transmission. J Infect Dis 206:1504-1511. http://dx.doi.org/10.1093/infdis/jis571.
7. Das SR, Hensley SE, Ince WL, Brooke CB, Subba A, Delboy MG, Russ G, Gibbs JS, Bennink JR, Yewdell JW. 2013. Defining influenza A virus hemagglutinin antigenic drift by sequential monoclonal antibody selection. Cell Host Microbe 13:314-323. http://dx.doi.org/10.1016/j.chom.2013.02.008.
8. Park AW, Daly JM, Lewis NS, Smith DJ, Wood JLN, Grenfell BT. 2009. Quantifying the impact of immune escape on transmission dynamics of influenza. Science 326:726-728. http://dx.doi.org/10.1126/science.1175980.
9. Sheu TG, Fry AM, Garten RJ, Deyde VM, Shwe T, Bullion L, Peebles PJ, Li Y, Klimov AI, Gubareva LV. 2011. Dual resistance to adamantanes and oseltamivir among seasonal influenza A(H1N1) viruses: 2008-2010. J Infect Dis 203:13-17. http://dx.doi.org/10.1093/infdis/jiq005.
10. Domingo-Calap P, Cuevas JM, Sanjuán R. 2009. The fitness effects of random mutations in single-stranded DNA and RNA bacteriophages. PLoS Genet 5:e1000742. http://dx.doi.org/10.1371/journal.pgen.1000742.
11. Carrasco P, de la Iglesia F, Elena SF. 2007. Distribution of fitness and virulence effects caused by single-nucleotide substitutions in tobacco etch virus. J Virol 81:12979-12984. http://dx.doi.org/10.1128/JVI.00524-07.
12. Sanjuán R, Moya A, Elena SF. 2004. The distribution of fitness effects caused by single-nucleotide substitutions in an RNA virus. Proc Natl Acad Sci USA 101:8396-8401. http://dx.doi.org/10.1073/pnas.0400146101.
13. Bull JJ, Sanjuan R, Wilke CO. 2007. Theory of lethal mutagenesis for viruses. J Virol 81:2930-2939. http://dx.doi.org/10.1128/JVI.01624-06.
14. Lauring AS, Andino R. 2010. Quasispecies theory and the behavior of RNA viruses. PLoS Pathog 6:e1001005. http://dx.doi.org/10.1371/journal.ppat.1001005.
15. Crotty S, Cameron CE, Andino R. 2001. RNA virus error catastrophe: direct molecular test by using ribavirin. Proc Natl Acad SciUS A 98:6895-6900. http://dx.doi.org/10.1073/pnas.111085598.
16. Severson WE, Schmaljohn CS, Javadian A, Jonsson CB. 2003. Ribavirin causes error catastrophe during Hantaan virus replication. J Virol 77:481-488. http://dx.doi.org/10.1128/JVI.77.1.481-488.2003.
17. Moreno H, Gallego I, Sevilla N, de la Torre JC, Domingo E, Martin V. 2011. Ribavirin can be mutagenic for arenaviruses. J Virol 85:7246-7255. http://dx.doi.org/10.1128/JVI.00614-11.
18. Lanford RE, Chavez D, Guerra B, Lau JYN, Hong Z, Brasky KM, Beames B. 2001. Ribavirin induces error-prone Replication of GB virus B in primary tamarin hepatocytes. J Virol 75:8074-8081. http://dx.doi.org/10.1128/JVI.75.17.8074-8081.2001.
19. Day C, Smee D, Julander J, Yamshchikov V, Sidwell R, Morrey J. 2005. Error-prone replication of West Nile virus caused by ribavirin. Antiviral Res 67:38-45. http://dx.doi.org/10.1016/j.antiviral.2005.04.002.
20. Shah NR, Sunderland A, Grdzelishvili VZ. 2010. Cell type mediated resistance of vesicular stomatitis virus and Sendai virus to ribavirin. PLoS One 5:e11265. http://dx.doi.org/10.1371/journal.pone.0011265.
21. Dietz J, Schelhorn S-E, Fitting D, Mihm U, Susser S, Welker M-W, Fuller C, Daumer M, Teuber G, Wedemeyer H, Berg T, Lengauer T, Zeuzem S, Herrmann E, Sarrazin C. 2013. Deep sequencing reveals mutagenic effects of ribavirin during monotherapy of hepatitis C virus genotype 1-infected patients. J Virol 87:6172-6181. http://dx.doi.org/10.1128/JVI.02778-12.
22. Brillanti S, Mazzella G, Roda E. 2011. Ribavirin for chronic hepatitis C: and the mystery goes on. Dig Liver Dis 43:425-430. http://dx.doi.org/10.1016/j.dld.2010.10.007.
23. Dapp MJ, Clouser CL, Patterson S, Mansky LM. 2009. 5-Azacytidine can induce lethal mutagenesis in human immunodeficiency virus type 1. J Virol 83:11950-11958. http://dx.doi.org/10.1128/JVI.01406-09.
24. Sierra S, Davila M, Lowenstein PR, Domingo E. 2000. Response of foot-and-mouth disease virus to increased mutagenesis: influence of viral load and fitness in loss of infectivity. J Virol 74:8316-8323. http://dx.doi.org/10.1128/JVI.74.18.8316-8323.2000.
25. Ruiz-Jarabo CM, Ly C, Domingo E, de la Torre JC. 2003. Lethal mutagenesis of the prototypic arenavirus lymphocytic choriomeningitis virus (LCMV). Virology 308:37-47. http://dx.doi.org/10.1016/S0042-6822(02)00046-6.
26. Smith EC, Blanc H, Vignuzzi M, Denison MR. 2013. Coronaviruses lacking exoribonuclease activity are susceptible to lethal mutagenesis: evidence for proofreading and potential therapeutics. PLoS Pathog 9:e1003565. http://dx.doi.org/10.1371/journal.ppat.1003565.
27. Graci JD, Cameron CE. 2008. Therapeutically targeting RNA viruses via lethal mutagenesis. Future Virol 3:553-566. http://dx.doi.org/10.2217/17460794.3.6.553.
28. Jackson-Grusby L, Laird PW, Magge SN, Moeller BJ, Jaenisch R. 1997. Mutagenicity of 5-aza-2=-deoxycytidine is mediated by the mammalian DNA methyltransferase. Proc Natl Acad Sci USA 94:4681-4685. http://dx.doi.org/10.1073/pnas.94.9.4681.
29. Lee H-J, Pawlak K, Nguyen BT, Robins RK, Sadée W. 1985. Biochemical differences among four inosinate dehydrogenase inhibitors, mycophenolic acid, ribavirin, tiazofurin, and selenazofurin, studied in mouse lymphoma cell culture. Cancer Res 45:5512-5520.
30. Leyssen P, Balzarini J, De Clercq E, Neyts J. 2005. The Predominant mechanism by which ribavirin exerts its antiviral activity in vitro against flaviviruses and paramyxoviruses is mediated by inhibition of IMP dehydrogenase. J Virol 79:1943-1947. http://dx.doi.org/10.1128/JVI.79.3.1943-1947.2005.
31. Eriksson B, Helgstrand E, Johansson NG, Larsson A, Misiorny A, Noren JO, Philipson L, Stenberg K, Stening G, Stridh S, Oberg B. 1977. Inhibition of Influenza virus ribonucleic acid polymerase by ribavirin triphosphate. Antimicrob Agents Chemother 11:964-951.
32. Binh NT, Wakai C, Kawaguchi A, Nagata K. 2014. Involvement of the N-terminal portion of influenza virus RNA polymerase subunit PB1 in nucleotide recognition. Biochem Biophys Res Commun 443:975-979. http://dx.doi.org/10.1016/j.bbrc.2013.12.071.
33. Bougie I, Bisaillon M. 2004. The broad spectrum antiviral nucleoside ribavirin as a substrate for a viral RNA capping enzyme. J Biol Chem 279:22124-22130. http://dx.doi.org/10.1074/jbc.M400908200.
34. Ogbomo H, Michaelis M, Altenbrandt B, Doerr HW, Cinatl J. 2010. A novel immunomodulatory mechanism of ribavirin in suppressing natural killer cell function. Biochem Pharmacol 79:188-197. http://dx.doi.org/10.1016/j.bcp.2009.07.026.
35. Rigopoulou E, Abbott W, Williams R, Naoumov N. 2007. Direct evidence for immunomodulatory properties of ribavirin on T-cell reactivity to hepatitis C virus. Antiviral Res 75:36-42. http://dx.doi.org/10.1016/j.antiviral.2006.11.008.
36. Mondelli MU. 2014. The multifaceted functions of ribavirin: antiviral, immunomodulator, or both?. Hepatology 60:1126-1129. http://dx.doi.org/10.1002/hep.27186.
37. Freistadt M. 2004. Lethal mutagens: broad-spectrum antivirals with limited potential for development of resistance?. Drug Resist Updat 7:19-24. http://dx.doi.org/10.1016/j.drup.2003.12.003.
38. Pfeiffer JK, Kirkegaard K. 2003. A single mutation in poliovirus RNAdependent RNA polymerase confers resistance to mutagenic nucleotide analogs via increased fidelity. Proc Natl Acad Sci USA 100:7289-7294. http://dx.doi.org/10.1073/pnas.1232294100.
39. Zeng J, Wang H, Xie X, Yang D, Zhou G, Yu L. 2013. An increased replication fidelity mutant of foot-and-mouth disease virus retains fitness in vitro and virulence in vivo. Antiviral Res 100:1-7. http://dx.doi.org/10.1016/j.antiviral.2013.07.008.
40. Coffey LL, Beeharry Y, Borderia AV, Blanc H, Vignuzzi M. 2011. Arbovirus high fidelity variant loses fitness in mosquitoes and mice. Proc Natl Acad Sci USA 108:16038-16043. http://dx.doi.org/10.1073/pnas.1111650108.
41. Visser J, Hermisson J, Wagner GP, Meyers LA, Bagheri-Chaichian H, Blanchard JL, Chao L, Cheverud JM, Elena SF, Fontana W, et al. 2003. Perspective: evolution and detection of genetic robustness. Evolution 57: 1959-1972. http://dx.doi.org/10.1554/02-750R.
42. Sanjuán R, Cuevas JM, Furió V, Holmes EC, Moya A. 2007. Selection for robustness in mutagenized RNA viruses. PLoS Genet 3:e93. http://dx.doi.org/10.1371/journal.pgen.0030093.
43. Graci JD, Gnadig NF, Galarraga JE, Castro C, Vignuzzi M, Cameron CE. 2012. Mutational robustness of an RNA virus influences sensitivity to lethal mutagenesis. J Virol 86:2869-2873. http://dx.doi.org/10.1128/JVI.05712-11.
44. Wray S, Gilbert B, Noall M, Knight V. 1985. Mode of action of ribavirin: effect of nucleotide pool alterations on influenza virus ribonucleoprotein synthesis. Antiviral Res 5:29-37.
45. Cheung PPH, Watson SJ, Choy K-T, Fun Sia S, Wong DDY, Poon LLM, Kellam P, Guan Y, Malik Peiris JS, Yen H-L. 2014. Generation and characterization of influenza A viruses with altered polymerase fidelity. Nat Commun 5:4794. http://dx.doi.org/10.1038/ncomms5794.
46. Baranovich T, Wong S-S, Armstrong J, Marjuki H, Webby RJ, Webster RG, Govorkova EA. 2013. T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro. J Virol 87:3741-3751. http://dx.doi.org/10.1128/JVI.02346-12.
47. Arias A, Thorne L, Goodfellow I. 2014. Favipiravir elicits antiviral mutagenesis during virus replication in vivo. eLife 3:e03679. http://dx.doi.org/10.7554/eLife.03679.
48. Hoffmann E, Neumann G, Kawaoka Y, Hobom G, Webster RG. 2000. A DNA transfection system for generation of influenza A virus from eight plasmids. Proc Natl Acad Sci USA 97:6108-6113. http://dx.doi.org/10.1073/pnas.100133697.
49. Mosmann T. 1983. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55-63. http://dx.doi.org/10.1016/0022-1759(83)90303-4.
50. Balish AL, Katz JM, Klimov AI. 2013. Influenza: propagation, quantification, and storage. Curr Protoc Microbiol 15G.1. http://dx.doi.org/10.1002/9780471729259.mc15g01s29.
51. Reed LJ, Muench H. 1938. A simple method of estimating fifty per cent endpoints. Am J Epidemiol 27:493-497.
52. Zhou B, Donnelly ME, Scholes DT, St George K, Hatta M, Kawaoka Y, Wentworth DE. 2009. Single-reaction genomic amplification accelerates sequencing and vaccine production for classical and swine origin human influenza A viruses. J Virol 83:10309-10313. http://dx.doi.org/10.1128/JVI.01109-09.
53. Langmead B, Trapnell C, Pop M, Salzberg SL, others. 2009. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol 10:R25. http://dx.doi.org/10.1186/gb-2009-10-3-r25.
54. Gerstung M, Beisel C, Rechsteiner M, Wild P, Schraml P, Moch H, Beerenwinkel N. 2012. Reliable detection of subclonal single-nucleotide variants in tumour cell populations. Nat Commun 3:811. http://dx.doi.org/10.1038/ncomms1814.
55. Anderson JP, Daifuku R, Loeb LA. 2004. Viral error catastrophe by mutagenic nucleosides. Annu Rev Microbiol 58:183-205. http://dx.doi.org/10.1146/annurev.micro.58.030603.123649.
56. Li M-H, Ito D, Sanada M, Odani T, Hatori M, Iwase M, Nagumo M. 2004. Effect of 5-fluorouracil on G1 phase cell cycle regulation in oral cancer cell lines. Oral Oncol 40:63-70. http://dx.doi.org/10.1016/S1368-8375(03)00136-2.
57. Krečmerová M, Otmar M. 2012. 5-Azacytosine compounds in medicinal chemistry: current stage and future perspectives. Future Med Chem 4:991-1005. http://dx.doi.org/10.4155/fmc.12.36.
58. Beaucourt S, Bordería AV, Coffey LL, Gnädig NF, Sanz-Ramos M, Beeharry Y, Vignuzzi M. 2011. Isolation of fidelity variants of RNA viruses and characterization of virus mutation frequency. J Vis Exp 16: 2953. http://dx.doi.org/10.3791/2953.
59. Furuta Y, Takahashi K, Kuno-Maekawa M, Sangawa H, Uehara S, Kozaki K, Nomura N, Egawa H, Shiraki K. 2005. Mechanism of action of T-705 against influenza virus. Antimicrob Agents Chemother 49:981-986. http://dx.doi.org/10.1128/AAC.49.3.981-986.2005.
60. Carr S, Papp E, Wu J, Natsumeda Y. 1993. Characterization of human type I and type I1 IMP dehydrogenases. J Biol Chem 268:27286-27290.
61. Nayak DP. 1980. Defective interfering influenza viruses. Annu Rev Microbiol 34:619-644. http://dx.doi.org/10.1146/annurev.mi.34.100180.003155.
62. Thompson KA, Yin J. 2010. Population dynamics of an RNA virus and its defective interfering particles in passage cultures. Virol J 7:257. http://dx.doi.org/10.1186/1743-422X-7-257.
63. Grande-Pérez A, Lázaro E, Lowenstein P, Domingo E, Manrubia SC. 2005. Suppression of viral infectivity through lethal defection. Proc Natl Acad Sci USA 102:4448-4452. http://dx.doi.org/10.1073/pnas.0408871102.
64. Kawakami E, Watanabe T, Fujii K, Goto H, Watanabe S, Noda T, Kawaoka Y. 2011. Strand-specific real-time RT-PCR for distinguishing influenza vRNA, cRNA, and mRNA. J Virol Methods 173:1-6. http://dx.doi.org/10.1016/j.jviromet.2010.12.014.
65. Lauring AS, Acevedo A, Cooper SB, Andino R. 2012. Codon usage determines the mutational robustness, evolutionary capacity, and virulence of an RNA virus. Cell Host Microbe 12:623-632. http://dx.doi.org/10.1016/j.chom.2012.10.008.
66. Plotkin JB, Dushoff J. 2003. Codon bias and frequency-dependent selection on the hemagglutinin epitopes of influenza A virus. Proc Natl Acad Sci USA 100:7152-7157. http://dx.doi.org/10.1073/pnas.1132114100.
67. Hoopes JD, Driebe EM, Kelley E, Engelthaler DM, Keim PS, Perelson AS, Rong L, Went GT, Nguyen JT. 2011. Triple combination antiviral drug (TCAD) composed of amantadine, oseltamivir, and ribavirin impedes the selection of drug-resistant influenza A Virus. PLoS One 6:e29778. http://dx.doi.org/10.1371/journal.pone.0029778.